Science First | Clinical study

Xeal™ and TiUltra™ surfaces support
excellent peri-implant tissue health1-year results from a prospective clinical trial

Excellent soft tissue health and stable
marginal bone levels after initial remodelingwith NobelActive® TiUltra implants andOn1™ Base Xeal at 1-year follow-up
Clinical Study with Gradually Anodized Implants Restored with Two-Piece Anodized
Abutments – 1-Year Results. Giacomo Fabbri and Giorgio Ban. Presented at the Annual
Meeting of the Academy of Osseointegration Feb. 24 – 26, 2022 San Diego, CA, USA.

The results‒ 96.5% cumulative implantsurvival rate at 1 year
‒ Excellent soft tissue response with
continuous improvement in keratinized

Study design

mucosa presence and height, bleeding andgingival indices, and Jemt’s papilla score

Prospective, single-center
Inclusion criteria:‒ Single tooth

19%

77%

‒ Healed sites‒ Premolar or molar

full papillaheightregenerated
at 1 year‒ Maxilla or mandible
61 implants placed

More thanhalf ofpapilla heightregenerated
at 1 year

Papillaregeneration‒ Stable marginal bone levels from prosthetic
61 implants restored withdefinitive prosthesis

56 implants
evaluated at 1 year

Clinical relevance
Excellent peri-implant soft tissue health withrobust regeneration of the papilla by 1 year

remodeling following implant insertion

Marginal Bone Level (mm)55 implants
evaluated at 6 months

delivery to 1 year after the expected20-0.04

-1.12

-1.08

-1.36

-2
-4
-6
Implant
insertion
n=61

Prosthetic
deliveryn=60

6 monthsn=52

1 yearn=55‒ Improved oral health-related quality of

Stable marginal bone levels after the initialremodeling post-insertion

life with the OHIP-14 score decrease fromHigh patient satisfaction and improved oral
health-related quality of life

delivery and 0.0 at 1 year. Very highConfirms benefits of the On1 concept, whereby
the On1 Base is seated at the time of implant
placement and not disconnected thereafter.

esthetics, with mean scores of ≥9.7, on a

1.1 at pre-treatment to 0.1 at prosthetic
patient satisfaction with function andscale from 0 to 10, at all follow-up visitsSample clinical case from the study
Implant insertion

Prosthetic delivery

6 months

1 yearClinical views (top row) and peri-apical radiographs (bottom row) at indicated time points. A 43-year-old female patient,non-smoker, reported with a missing first molar tooth in the mandible (FDI position 36) and received NobelActive
TiUltra RP 4.3 x 10mm. Following the digital impression, an On1 Base Xeal and an On1 healing cap were placed on topof the implant. The final prosthesis was delivered 6.7 months later and consisted of an On1 universal abutment and aNobelProcera® full-contour zirconia crown. Note the improvement of soft tissue health throughout the follow-up andmarginal bone level stability following the initial remodeling.

Xeal and TiUltra are well-documented,
clinically proven surfaces
In published studies as of February 2022

235 patients
377 TiUltra implants
160 Xeal abutments

Xeal and TiUltra
surfaces support
excellent soft tissue
integration andhealthy marginal
bone response

More to explore

View poster on
the AO2022 website

FOR - Spotlight onsurface innovations

nobelbiocare.com/en-us/surfaces

MKT-5153 Rev 00 (06/22, GMT 80193) © Nobel Biocare USA, LLC, 2022. All rights reserved. Nobel Biocare, the Nobel Biocare logotype
and all other trademarks are, if nothing else is stated or is evident from the context in a certain case, trademarks of Nobel Biocare.
Please refer to nobelbiocare.com/trademarks for more information. Product images are not necessarily to scale. All product images arefor illustration purposes only and may not be an exact representation of the product. Disclaimer: Some products may not be regulatory
cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office for current product assortment andavailability. See Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions.